The most significant advance in glioma treatment in two decades
No Brasil, a aprovação de um comprimido diário para tumores cerebrais de baixo grau marca o avanço mais expressivo no tratamento de gliomas em duas décadas. O medicamento Voranigo, desenvolvido pelo laboratório Servier, age sobre mutações genéticas específicas presentes em células tumorais, interrompendo o processo molecular que alimenta seu crescimento. Sua chegada oferece a pacientes a partir dos doze anos — muitos deles jovens que carregam esse diagnóstico por toda uma vida — uma alternativa mais tolerável à radioterapia e à quimioterapia, redesenhando o que significa conviver com essa doença.
- Gliomas de baixo grau afetam sobretudo jovens e, até agora, deixavam médicos e famílias diante de uma escolha difícil: esperar o tumor crescer ou submeter o paciente a tratamentos agressivos.
- A aprovação da Anvisa rompe esse impasse ao oferecer um comprimido diário que pode ser tomado em casa, com efeitos colaterais significativamente menores do que os das terapias convencionais.
- O Voranigo age diretamente nas enzimas IDH1 e IDH2 mutadas, bloqueando a produção de substâncias que nutrem as células cancerígenas — uma abordagem molecular inédita no arsenal clínico brasileiro.
- Oncologistas descrevem a aprovação como um divisor de águas, capaz de adiar por anos procedimentos mais invasivos e preservar a qualidade de vida de pacientes em fase escolar ou no início da vida adulta.
- O tratamento está disponível para pacientes com 12 anos ou mais que já passaram por cirurgia e ainda não necessitam de radioterapia ou quimioterapia imediata, abrindo uma janela terapêutica antes inexistente.
A Anvisa aprovou o Voranigo, um comprimido diário desenvolvido pela Servier para o tratamento de gliomas cerebrais de baixo grau com mutações nas enzimas IDH1 ou IDH2. Especialistas descrevem a decisão como o avanço mais relevante no campo em vinte anos. O medicamento é indicado para pacientes a partir dos doze anos que já realizaram cirurgia e não precisam, de imediato, de radioterapia ou quimioterapia.
Esses tumores — entre eles astrocitomas e oligodendrogliomas — costumam surgir em pessoas jovens e acompanhá-las por décadas. Até agora, a conduta padrão após a cirurgia era observar e aguardar, recorrendo a tratamentos mais agressivos apenas quando o tumor voltasse a crescer. O Voranigo propõe um caminho diferente: agir na raiz molecular do problema, bloqueando as enzimas mutadas que alimentam a proliferação das células cancerígenas.
O que torna essa aprovação especialmente significativa é sua forma. Um comprimido tomado diariamente em casa representa uma ruptura com o peso físico e emocional da quimioterapia e da radioterapia. Para jovens que podem viver décadas com o diagnóstico, a possibilidade de controlar a doença com menor impacto no cotidiano não é apenas um avanço clínico — é uma transformação concreta na experiência de adoecer. O oncologista Fernando Maluf destacou que o medicamento oferece aos médicos uma via intermediária: nem a espera passiva, nem o tratamento imediato e invasivo, mas uma gestão ativa e tolerável da doença, capaz de preservar a qualidade de vida e adiar escolhas mais difíceis por anos.
Brazil's health regulator has approved a new daily pill for treating a specific type of brain cancer, marking what specialists are calling the most significant advance in glioma treatment in two decades. The drug, called Voranigo, made by pharmaceutical company Servier, targets low-grade brain tumors that carry mutations in the IDH1 or IDH2 enzymes—genetic alterations found in some of the most common cancers that develop in the brain.
The approval applies to patients as young as twelve years old who have already undergone surgery for these tumors and are not immediately facing radiation or chemotherapy. These low-grade gliomas, which include astrocytomas and oligodendrogliomas, tend to strike young people, sometimes appearing in childhood and extending into early adulthood. Until now, the standard approach for managing them after surgery was to wait and watch, then resort to radiation or chemotherapy when the tumor began to grow again.
Voranigo works by blocking the mutated enzymes that produce substances fueling tumor cell growth. By interrupting this process at the molecular level, the medication aims to slow or prevent the cancer's progression. Oncologist Fernando Maluf, speaking to Brazil's national news agency, described the approval as a watershed moment. He emphasized that these tumors are among the most frequently diagnosed brain cancers, and the new option represents a fundamentally different approach to managing them in younger patients who might otherwise face decades of aggressive treatment cycles.
What makes this approval significant is not just the mechanism but the form. A daily oral tablet offers patients something previous options could not: a treatment they can take at home with manageable side effects, rather than enduring the physical toll of radiation or the systemic effects of chemotherapy. For young people facing a potentially long life with cancer, this distinction matters enormously. The medication provides a way to buy time, to keep the disease in check while avoiding or delaying more invasive procedures.
Maluf noted that the drug's tolerability profile and its demonstrated ability to reduce the risk of tumor progression make it a genuinely new tool in the oncologist's arsenal. Rather than forcing an immediate choice between surgery and aggressive treatment, doctors can now offer patients a middle path—a way to manage their disease with a pill taken each day, potentially preserving their quality of life and deferring harder choices for years. For families of young patients, and for the patients themselves, this represents not just a medical advance but a shift in what living with this diagnosis might look like.
Citas Notables
The biggest advance in glioma treatment in the last twenty years— Oncologist Fernando Maluf
The medication offers an important alternative capable of delaying further surgeries or more aggressive treatments, with good tolerability and significant impact on reducing disease progression risk— Fernando Maluf
La Conversación del Hearth Otra perspectiva de la historia
Why does it matter that this is a pill rather than an injection or infusion?
Because a twelve-year-old taking this drug will take it at home, on their own schedule, without needing hospital visits or watching their body respond to poisons designed to kill fast-dividing cells. It's the difference between managing a disease and enduring treatment.
These are low-grade tumors. Are they not already slow-growing?
They are, which is exactly why the old approach was to watch and wait. But watching means living with uncertainty. This drug lets you actively slow something that will eventually grow. It's not passive anymore.
The doctor called it the biggest advance in twenty years. Is that hyperbole?
Not really. For two decades, if you had one of these tumors and surgery wasn't enough, your options were radiation or chemo—both brutal. Now there's a third path that doesn't destroy your body to fight the cancer. That's genuinely new.
Who benefits most from this?
Young people, mainly. Someone diagnosed at fifteen might take this pill for years, maybe decades, without ever needing radiation. Compare that to someone who gets blasted with radiation in their teens and lives with the neurological damage for fifty years.
Does this cure the cancer?
No. It slows it, possibly for a long time. But for a disease that's already slow-growing, slowing it further while keeping someone functional and at home—that's not a cure, but it's a life.